Insulin-like Growth Factor (igf) Or Derivative Patents (Class 514/8.5)
-
Publication number: 20120149641Abstract: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Applicant: GENERA ISTRAZIVANJA d.o.o.Inventors: Slobodan VUKICEVIC, Mislav JELIC
-
Publication number: 20120141555Abstract: The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.Type: ApplicationFiled: January 24, 2012Publication date: June 7, 2012Inventor: Arne Briest
-
Publication number: 20120141430Abstract: The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.Type: ApplicationFiled: January 12, 2010Publication date: June 7, 2012Inventors: Michael Friedman, Yoel Sasson, Ada Grin, Rami Mosheiff, Jacob Rachmilewitz
-
Publication number: 20120129772Abstract: There is disclosed a method of inhibiting angiogenesis in a patient having an angiogenic associated disorder comprising administering to said patient a therapeutically effective amount of a soluble IGF-IR protein. The use of such soluble IGF-IR protein for inhibiting angiogenesis in a patient is also disclosed.Type: ApplicationFiled: July 28, 2009Publication date: May 24, 2012Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/McGILL UNIVERSITYInventors: Pnina Brodt, Zhipeng You
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Patent number: 8173118Abstract: This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers (e.g., compositions comprising TGF-?1, BMP-2, FGF-4, and leukemia inhibitory factor), and methods for repairing cardiovascular tissue are provided.Type: GrantFiled: July 29, 2005Date of Patent: May 8, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Andre Terzic, Atta Behfar
-
Publication number: 20120100185Abstract: The present invention provides methods and compositions for tissue regeneration without cell transplantation.Type: ApplicationFiled: April 13, 2010Publication date: April 26, 2012Inventors: Xuejun Wen, Yongzhi Qiu, Wendy S. Vanden Berg-Foels
-
Publication number: 20120093798Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: August 19, 2008Publication date: April 19, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Patent number: 8158581Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: GrantFiled: September 30, 2010Date of Patent: April 17, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Publication number: 20120088721Abstract: This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.Type: ApplicationFiled: March 22, 2010Publication date: April 12, 2012Applicant: GENZYME CORPORATIONInventors: Aviva Shiedlin, Timothy J. Butler, Michael Philbrook, Peter K. Jarrett
-
Publication number: 20120076837Abstract: In one aspect, the invention relates to providing enhanced application tissue graft materials in regenerative medicine through improved cellular interactions. Biocompatible implant materials, methods for preparing biocompatible implant materials, methods for using same, and methods for treating tissue injury are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 2, 2011Publication date: March 29, 2012Inventors: V. Prasad Shastri, Henrique Franca Diniz Oliveira
-
Publication number: 20120077742Abstract: Recombinant NELL peptides and methods of preparing the same are disclosed.Type: ApplicationFiled: October 5, 2011Publication date: March 29, 2012Applicant: The Regents of the University of CaliforniaInventors: Kang Ting, Shunichi Kuroda, Ben Wu
-
Publication number: 20120070485Abstract: The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer material. An active ingredient is advantageously dispersed in the fibrin layer. The fibrin layer does not have a haemostatic function, but is suitable for retaining the active ingredient and releasing it with controlled kinetics. The device forming the object of the invention, preferably in the form of patches, is useful for in vitro cell cultures or for treating tissues damaged by wounds or necrosis, such as cardiac walls bearing the sequelae of infarction, or a tissue damaged by a diabetic ulcer.Type: ApplicationFiled: May 26, 2010Publication date: March 22, 2012Inventors: Giorgio Soldani, Enrica Briganti
-
Patent number: 8133862Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.Type: GrantFiled: March 16, 2009Date of Patent: March 13, 2012Assignee: Tercica, Inc.Inventor: Ross G. Clark
-
Publication number: 20120058120Abstract: Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether a candidate agent can modulate an interaction between a transglutaminase and an insulin-like growth factor and/or a member of the IGF family of receptors. Also provided are pharmaceutical compositions and methods of treatment using said pharmaceutical compositions.Type: ApplicationFiled: March 19, 2010Publication date: March 8, 2012Inventors: Tristan Croll, Gary Keith Shooter, Jesse Ray Peet, Simone Rizzl, Derek Robert Von Lonkhuyzen, Zee Upton
-
Publication number: 20120058938Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.Type: ApplicationFiled: March 9, 2010Publication date: March 8, 2012Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph Hageman, Mirian Lansink
-
Publication number: 20120058190Abstract: A nutritional Composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event.Type: ApplicationFiled: February 17, 2010Publication date: March 8, 2012Applicant: Technion-Research & Development Foundation LtdInventor: Naim Shehadeh
-
Patent number: 8124130Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations of the present invention preferably include platelet-rich plasma with a pharmaceutical agent. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4), bisphosphonates, derivatives thereof, and combinations thereof. The formulations of the present invention may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.Type: GrantFiled: May 30, 2008Date of Patent: February 28, 2012Inventor: James Louis Rutkowski
-
Publication number: 20120045487Abstract: A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and is formed by electrohydrodynamic jetting. Further, such microfibers optionally have one or more biofunctional agents, which may be surface-bound moieties provided in spatial patterns. Multiphasic microfibers formed in accordance with the disclosure may form, in some cases, three-dimensional fiber scaffolds with precisely engineered, micrometer-scaled patterns for cellular contact guidance, which may thus support and/or promote cellular growth, proliferation, differentiation, repair, and/or regeneration for tissue and bioengineering applications.Type: ApplicationFiled: April 29, 2010Publication date: February 23, 2012Applicant: The Regents of the University of MichiganInventors: Joerg Lahann, Srijanani Bhaskar, Suparna Mandal
-
Patent number: 8114428Abstract: The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.Type: GrantFiled: September 7, 2009Date of Patent: February 14, 2012Assignee: SBF Synthetic Bone Factory GmbHInventor: Arne Briest
-
Publication number: 20120021983Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, TUFTS MEDICAL CENTER, INC.Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
-
Patent number: 8101198Abstract: An osteogenic enhancer composition for bone and cartilage repair and methods of using the same are described.Type: GrantFiled: July 25, 2007Date of Patent: January 24, 2012Assignee: The Regents of the University of CaliforniaInventors: Takahiro Ogawa, Anahid Jewett
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION
Publication number: 20120014879Abstract: Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.Type: ApplicationFiled: October 24, 2006Publication date: January 19, 2012Applicant: CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON INCInventors: Douglas W. Losordo, David A. Goukassian -
Publication number: 20120010139Abstract: Thermal responsive compositions for treating bone diseases are provided. The thermal responsive composition for treating bone diseases includes a bone growth factor and a biodegradable copolymer. The biodegradable copolymer has a structure of Formula (I) or Formula (II): A-B-BOX-B-A??(Formula I) and B-A-B-(BOX-B-A-B)n-BOX-B-A-B??Formula (II), wherein, A includes a hydrophilic polyethylene glycol polymer, B includes a hydrophobic polyester polymer, BOX is a bifunctional group monomer of 2,2?-Bis(2-oxazoline) and used for coupling the blocks A-B or B-A-B, and n is an integer and the same or more than 0.Type: ApplicationFiled: June 29, 2011Publication date: January 12, 2012Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Shen-Hua Peng, Hsin-Hsin Shen, Liang-Yo Yang, Meng-Yow Hsieh, Pei-Shan Li, Wei-Lin Yu, Tsai-Yu Lin, Po-Liang Lai, Jui-Sheng Sun, Chih-Hung Chang, Yi-Hung Lin
-
Publication number: 20120009260Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.Type: ApplicationFiled: June 10, 2011Publication date: January 12, 2012Inventors: Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos
-
Publication number: 20110318424Abstract: The present invention is directed to the use of modulators of the mammalian target of rapamycine (mTOR) pathway, glucose and/or glucose enhancers for treating retinal disorders and, in particular, for prolonging the viability of cone cells.Type: ApplicationFiled: December 3, 2009Publication date: December 29, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Constance Louise Cepko, Claudio Punzo
-
Publication number: 20110305710Abstract: This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells.Type: ApplicationFiled: May 14, 2011Publication date: December 15, 2011Inventor: Muhammad Abdulrazik
-
Publication number: 20110305760Abstract: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.Type: ApplicationFiled: June 9, 2010Publication date: December 15, 2011Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: William L. Murphy, Mark D. Markel, Ben K. Graf, Yan Lu, Jae Sung Lee
-
Publication number: 20110300184Abstract: Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.Type: ApplicationFiled: October 4, 2010Publication date: December 8, 2011Applicant: The Regents of the University of CaliforniaInventors: Chia Soo, Kang Ting, Shunichi Kuroda, Ben Wu
-
Publication number: 20110288363Abstract: Compositions, systems and methods utilizing engineered surgical irrigants providing delivery of components with therapeutic or other secondary benefits. Engineered irrigants provide targeted delivery of desired agents, including agents for propulsion of nano-devices, agents including molecular probes, gene expression agents, magnetically orientable agents, agents for discrete tissue temperature detection and tissue regeneration agents.Type: ApplicationFiled: May 27, 2011Publication date: November 24, 2011Applicant: NuOrtho Surgical Inc.Inventors: Roy E. Morgan, Wayne K. Auge, II
-
Patent number: 8053412Abstract: Recombinant NELL peptides and methods of preparing the same are disclosed.Type: GrantFiled: February 4, 2010Date of Patent: November 8, 2011Assignee: The Regents of the University of CaliforniaInventors: Kang Ting, Shunichi Kuroda, Ben Wu
-
Publication number: 20110262518Abstract: An injectable, high potency (high capillary force) composite comprised of bioceramic spheres having a smooth porous macroarchitecture and porous microarchitecture with interconnected pores and may be combined with various electrospun polymer fibers, thus achieving a biphasic composite implant device whereby a primary phase stabilizes, reinforces, restricts and constricts the expansion of dysfunctional and diseased cardiac muscle tissue, and a secondary phase providing a matrix structure within the bioceramic composite for the regeneration of dysfunctional and diseased cardiac tissue; an injectable composite implant material containing pharmaceutical agents or may contain stem cells, and other DNA materials; an injectable, high potency, bioceramic composite material providing a specific means to alter cardiac muscle geometry so as to normalize cardiac wall stress, aid in the reduction of local stresses in the border zone or in the actual infarct as well as multiple peri-infarct border zone modifications that hType: ApplicationFiled: April 27, 2010Publication date: October 27, 2011Inventors: Stuart K.J. Smyth, Jeanne M. Lesniak
-
Publication number: 20110256089Abstract: Disclosed is a hydrogel type cell delivery vehicle composition for wound healing and to a preparation method thereof. More particularly, the present invention relates to a hydrogel type cell delivery vehicle composition in which non-ionic surfactants, growth factors or substance-P, human-derived cells, and the like are distributed in aqueous media, to a use thereof for wound healing, and to a preparation method thereof. The hydrogel type composition of the present invention appropriately delivers cells and/or substance-P to the wound part, and has moistening effects, effects of preventing contraction of the wound, and effects of protecting cells, and can be used in an easy and convenient manner. The cells in the composition are delivered to the wound part to effectively heal the wound when the composition of the present invention is applied to or injected into the wounded body part.Type: ApplicationFiled: November 3, 2009Publication date: October 20, 2011Applicant: MODERN CELL & TISSUE TECHNOLOGIES INC.Inventors: Sae-Hwan Lim, Yun Young Kim, So Hee Yun
-
Publication number: 20110256095Abstract: The present application discloses matrix compositions to support the repair of tissue defects such as an injury to tendon tissue, ligament tissue, vascular tissue, dermal tissue, or muscle tissue. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix, and methods of using a matrix in the repair of tissue. In certain configurations, a matrix can comprise a polyester cross-linked with a polysaccharide, which can be an oxidized polysaccharide. In some configurations, a matrix can further comprise one or more additional components, such as a growth factor or an anti-infective agent. In some configurations, a matrix can be a viscous fluid or a paste, while in other configurations a matrix can be comprised by a solid such as a plug, a granule or a membrane.Type: ApplicationFiled: June 23, 2011Publication date: October 20, 2011Applicant: ISTO TECHNOLOGIES, INC.Inventors: Mitchell S. Seyedin, Gary Gage
-
Patent number: 8039434Abstract: A method is provided for producing hIGF-I with high purity and yield. This is a method for producing human insulin-like growth factor I, having a step of removing modified human insulin-like growth factor I from the human insulin-like growth factor I, the step including: (A) a step of adjusting the pH of a culture liquid of a human insulin-like growth factor I producing bacteria to 8 or more after completion of culture; (B) a step of letting the culture liquid obtained in step (A) stand; and (C) a step of removing the producing bacteria from the culture liquid obtained in step (B).Type: GrantFiled: April 30, 2008Date of Patent: October 18, 2011Assignee: Ajinomoto Co., Inc.Inventor: Teruhisa Mannen
-
Publication number: 20110250167Abstract: The present invention provides methods and kits for purifying a target protein group. The method comprises the steps of contacting a sample comprising at least 95% of the target protein group and at most 5% of contaminating proteins with a library of binding moieties having different binding moieties, binding the contaminating proteins and a minority of the target protein group to the library of binding moieties, separating the unbound target protein group from the proteins bound to the library of binding moieties and collecting the unbound target protein. The collected target protein is more pure than the target protein group in the sample.Type: ApplicationFiled: June 24, 2010Publication date: October 13, 2011Applicant: BIO-RAD LABORATORIES, INC.Inventors: Egisto Boschetti, Lee O. Lomas
-
Publication number: 20110245164Abstract: Insulin-like growth factor analogs are disclosed wherein substitution of the IGF native amino acids, at positions corresponding to positions B16 and B17 of native insulin, with tyrosine and leucine, respectively, increases potency of the resulting analog at the insulin receptor by tenfold. Also disclosed are prodrug and depot formulations of the IGF analogs, wherein the IGF analog has been modified by the linkage of a dipeptide to the analog through an amide bond linkage. The prodrug and depot formulations disclosed herein have extended half lives of at least 2 hours, 10 hours, and more typically greater than 2 are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: ApplicationFiled: December 18, 2009Publication date: October 6, 2011Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Richard D. DiMarchi, Shujiang Cheng, Binbin Kou, Jie Han
-
Publication number: 20110218145Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.Type: ApplicationFiled: November 10, 2009Publication date: September 8, 2011Applicant: NOVARTIS AGInventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
-
Publication number: 20110207662Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: ApplicationFiled: April 27, 2011Publication date: August 25, 2011Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20110182963Abstract: An osteoimplant is disclosed and includes a plurality of partially demineralized fibers. Each fiber has an elongated, thin body having a length of about 1 centimeter to about 3 centimeters. Further, the plurality of fibers engages to establish a matrix of material. The disclosure is further directed to a method of making the above-mentioned osteoimplant.Type: ApplicationFiled: January 28, 2010Publication date: July 28, 2011Applicant: WARSAW ORTHOPEDIC, INC.Inventor: William F. McKay
-
Publication number: 20110182911Abstract: A method of retaining growth factors on a substrate for release at a treatment region comprises immobilizing an antagonist of the growth factor on a substrate and binding of the growth factor to the antagonist. In one aspect, the substrate is provided on a bioimplant. The resulting bioimplant allows for activity of the growth factor to continue at the region of implantation. According to the method of the invention, exogenous growth factors can be used to stimulate the repair of various tissues and organs at the site requiring repair, and be protected from inactivation, sequestration or degradation. The invention also provides bioimplants and methods of delivering growth factors.Type: ApplicationFiled: January 3, 2011Publication date: July 28, 2011Applicant: INDUCE BIOLOGICS INC.Inventors: Cameron M. L. CLOKIE, Sean A. F. PEEL
-
Publication number: 20110178010Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: January 7, 2009Publication date: July 21, 2011Inventors: Johannes Gerhardus Maria Bolscher, Arie Van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem Van't Hof, Kamran Nazmi, Petronella Adriana Maria Van Den Keijbus
-
Publication number: 20110177140Abstract: This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the epidermal barrier. Barrier abnormalities and disruptions respectively are often the starting point of a dry skin state, of itching, of dandruff and of the perception of sensitive skin. These 4-amidino benzylamine derivatives can be used for topical skin and scalp care applications in form of creams, lotions, gels, shampoos and the like.Type: ApplicationFiled: August 31, 2007Publication date: July 21, 2011Inventors: Rainer Voegeli, Hugo Ziegler, Mathias Gempeler
-
Patent number: 7981864Abstract: Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.Type: GrantFiled: February 19, 2008Date of Patent: July 19, 2011Assignee: Biomarin Pharmaceutical Inc.Inventor: Jonathan LeBowitz
-
Publication number: 20110171283Abstract: The present invention relates to a composition containing at least one nutritive, at least one disinfecting or decontaminating and/or at least one protease-inhibiting active compound and/or active compound complex for the external care and/or treatment of wounds of the human or animal body.Type: ApplicationFiled: July 1, 2008Publication date: July 14, 2011Inventor: Birgit Riesinger
-
Patent number: 7968679Abstract: Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I/IGFBP-3 complexes.Type: GrantFiled: December 20, 2005Date of Patent: June 28, 2011Assignee: Insmed IncorporatedInventors: Mark C. Sleevi, Glen L. Kelley
-
Publication number: 20110152187Abstract: This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.Type: ApplicationFiled: August 5, 2008Publication date: June 23, 2011Applicant: ASTERION LIMITEDInventors: Peter Artymiuk, Richard Ross, Jon Sayers
-
Publication number: 20110144014Abstract: The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Applicant: CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINEInventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20110129462Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.Type: ApplicationFiled: November 24, 2010Publication date: June 2, 2011Applicant: AEGIS THERAPEUTICS LLCInventor: Edward T. Maggio